Fat Loss & Metabolism

Dulaglutide

Trulicity · weekly GLP-1 agonist

FDA-approvedpopularsubQ injection

What it is

Dulaglutide (brand name Trulicity) is Eli Lilly's weekly GLP-1 agonist, FDA-approved for type 2 diabetes in 2014 and cardiovascular risk reduction in 2020. It's primarily a glucose-control drug — weight loss is modest compared to semaglutide and tirzepatide.

How it works

Same mechanism as semaglutide: activates GLP-1 receptors to suppress appetite, slow gastric emptying, improve insulin sensitivity, and stimulate insulin release in a glucose-dependent way (low hypoglycemia risk).

Benefits

Strong glucose control (~1.5% HbA1c reduction)
Modest weight loss (3–5% body weight)
Cardiovascular event reduction (REWIND trial)
Once-weekly convenience
Works at lower doses than competitors

Timeline

Week 1–2: Glucose effects begin; mild appetite reduction.
Week 12: Full glucose control; 2–3% weight loss.
Week 26+: Plateau weight loss around 4–5%.

Dosing & titration

Starting dose0.75 mg subQ once weekly

Standard titration0.75 → 1.5 → 3.0 → 4.5 mg, every 4 weeks

Max dose4.5 mg/week

When to titrate upIf glucose targets aren't met after 4 weeks at current dose. Most weight-loss seekers prefer semaglutide or tirzepatide instead.

Side effects & risks

Nausea, vomiting, diarrhea
Decreased appetite
Hypoglycemia if combined with insulin or sulfonylureas
Rare: pancreatitis, gallstones

Black-box warning for medullary thyroid carcinoma in animals. Contraindicated in MEN-2 history.

Typical price

$900–$1,000/moBranded Trulicity retail. Compounded versions are rare.

Studies

Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — Major outcome trial. PubMedThe Lancet, 2019
Search PubMed for dulaglutide — PubMed searchLive PubMed search

Educational reference only. Not medical advice.